Phillip Oliver Coffin MD MIA, FACP, FIDSA (He/Him)

Internal Medicine•San Francisco, CA

Addiction Medicine, Hospital Medicine/Hospitalist, Infectious Disease

Director of Substance Use Research

Join to View Full Profile

25 Van Ness AveSuite 500San Francisco, CA 94102

Education & Training

University of WashingtonFellowship, Infectious Disease, 2009 - 2012
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2006 - 2009
University of California San Francisco School of MedicineClass of 2006

Certifications & Licensure

CA State Medical License 2012 - 2027
WA State Medical License 2009 - 2013
NY State Medical License 2007 - 2010
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease
American Board of Preventive Medicine Addiction Medicine

Clinical Trials

Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals Start of enrollment: 2009 Mar 01
Completed
Phase 2
Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors Start of enrollment: 2007 May 01
Completed
Phase 2
Reducing HIV Risk Among Episodic Substance Using Men Who Have Sex With Men (SUMSM) Start of enrollment: 2007 Sep 01
Completed
Phase 1, Phase 2
Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM) Start of enrollment: 2012 Sep 01
Completed
Phase 2
Intermittent Naltrexone Among Polysubstance Users Start of enrollment: 2013 May 01
Completed
Phase 2
Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0) Start of enrollment: 2013 Aug 01
Completed
Phase 2
Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Naloxone Recipients Start of enrollment: 2014 Jul 01
Completed
Not Applicable
Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs Start of enrollment: 2015 Dec 01
Completed
Phase 4
Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder Start of enrollment: 2017 May 05
Completed
Phase 3
Repeated-dose Behavioral Intervention to Reduce Opioid Overdose Start of enrollment: 2019 Apr 22
Completed
Not Applicable
PrEP Intervention for People Who Inject Substances and Use Methamphetamine Start of enrollment: 2021 Apr 30
Recruiting
Phase 4
Mirtazapine and Methamphetamine Drug-drug Interaction Study Start of enrollment: 2021 May 03
COMPLETED
PHASE1
Join now to see all

Publications & Presentations

PubMed

Barriers to Buprenorphine Treatment Among People Experiencing Homelessness: A Qualitative Study from the Provider Perspective.
Carmen L Masson, Kelly R Knight, Emily A Levine, Joseph A Spillane, Ya Chi Angelina Liang
Journal of Urban Health. 2025-03-27
Addressing Methamphetamine Use Is Essential to Stopping HIV Transmission.
Finn Black, Vanessa McMahan, Xochitl Luna Marti, Emily Pope, John Walker
Journal of Acquired Immune Deficiency Syndromes. 2025-02-01
1 citations
Identification of Behavioral, Clinical, and Psychological Antecedents of Acute Stimulant Poisoning: Development and Implementation of a Mixed Methods Psychological Aut...
Marley Antolin Muñiz, Vanessa M McMahan, Xochitl Luna Marti, Sarah Brennan, Sophia Tavasieff
JMIR Formative Research. 2025-01-13

Authored Content

Overdose Research PubMed UpdatesJanuary 2019

Press Mentions

S.F. Is Giving ‘Chill Packs’ to Homeless Meth Users. Why It May Be a Promising InterventionAugust 26th, 2024
Medication-Based Opioid Treatment on the Rise as San Francisco Grapples with OverdosesAugust 27th, 2022
As Meth Wreaks Havoc on SF Emergency Rooms, Urgency Grows for New TreatmentsAugust 23rd, 2022
Join now to see all

Grant Support

Midcareer K24 Award for Mentoring and Patient-Oriented ResearchSAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH2023–2028
Midcareer K24 Award for Mentoring and Patient-Oriented ResearchSAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH2023–2028
PRIME: PrEP Intervention for people who Inject MEthamphetaminePUBLIC HEALTH FOUNDATION ENTERPRISES2020–2025
PRIME: PrEP Intervention for people who Inject MEthamphetaminePUBLIC HEALTH FOUNDATION ENTERPRISES2020–2025
PRIME: PrEP Intervention for people who Inject MEthamphetaminePUBLIC HEALTH FOUNDATION ENTERPRISES2020–2025